Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% After Analyst Downgrade...
Wells Fargo & Company reduced their price objective on Kymera Therapeutics from $57.00 to $53.00 and...
8 analysts have expressed a variety of opinions on Kymera Therapeutics (NASDAQ:KYMR) over the past q...
HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the s...